Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 330

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 330
---
 express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2022.

San Diego, California

March 19, 2025

99

Table of Contents

LENZ THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except for shares and par value)

December 31,20242023AssetsCurrent assets:Cash and cash equivalents$20,158 $35,140 Marketable securities188,872 30,654 Prepaid expenses and other current assets2,773 1,450 Restricted cash114 — Total current assets211,917 67,244 Property and equipment, net651 54 Operating lease right-of-use asset1,338 318 Deferred offering costs— 2,739 Other assets1,398 21 Total assets$215,304 $70,376 Liabilities, convertible preferred and common stock and stockholders’ equity (deficit)Current liabilities:Accounts payable$4,257 $5,711 Accrued liabilities6,149 12,803 Total current liabilities10,406 18,514 Operating lease liability, net814 192 Other noncurrent liabilities— 121 Preferred stock warrants liability— 871 Total liabilities11,220 19,698 Commitments and contingencies (Note 7)Convertible preferred and common stock:Series A convertible preferred stock, par value of $0.001 per share; no shares and 22,791,777 shares authorized at December 31, 2024 and 2023, respectively; no shares and 21,977,282 shares issued and outstanding at December 31, 2024 and 2023, respectively— 44,621 Series A-1 convertible preferred stock, par value of $0.001 per share; no shares and 2,950,548 shares authorized at December 31, 2024 and 2023, respectively; no